Home » Dividend Updates » August 2019 Portfolio Update

As a dividend growth investor (DGI), I am driven to keep track of both my inflows and outflows. Increases in investment income represent one measure to assess whether I am winning or losing the game of money. After spending a full year tracking my dividend income on a monthly basis, I have noticed that I have a much better understanding of how my portfolio functions.

I have also improved as a capital allocator as I am not allowing dividends to sit idly for as long before putting them back to work to keep the dividend compounding machine firing on all cylinders.

CAD Dividends

CompanyCAD Payments ($)
RioCan Real Estate Investment Trust (REI.UN)31.32
Chartwell Retirement Residence (CSH.UN)5.00

USD Dividends

CompanyUSD Payments ($)
AbbVie Inc. (ABBV)40.02

Dividend Summary

I received C$36.32 and U$40.02 which brings me to a currency-neutral total of $76.34. This is identical to my totals from May. Since I haven’t added to positions which pay on this monthly or quarterly schedule, this comes as no surprise.

I have been eyeing another purchase of ABBV since the market has dragged it down over the impending Allergan (AGN) acquisition. My current cost basis is in the $83-84 range and so it would be possible to considerably average down on the stock since it has been trading in the $60s for around a month. The dividend has held steady and so lower prices mean a higher entry yield. I haven’t yet made my mind up on how to proceed; on one hand I would love to up my stake while on the other I am cautious of catching a falling knife.

My investment philosophy is generally to double down when the market offers an opportunity (after all, if you liked a stock at a higher price, you should be excited at the chance to buy more at a lower cost). However, the AGN situation changes the game as far as increasing the debt load and introducing execution risk on the part of management. I will nevertheless keep a close watch on the situation.

I would also note that at the time of writing, ABBV has just presented at the Morgan Stanley Healthcare Conference and it was indicated by the CEO, Rick Gonzalez, that ABBV has no exposure to opioid litigation (the unit responsible for the production of OxyContin within Abbott Laboratories (ABT) was entirely separate from the proprietary pharmaceutical business which became ABBV). Further, Rob Michael, CFO, indicated that the company feels very strongly that it will be able to continue with its history of strong dividend increases going forward based on post-AGN acquisition cash flows.

Year To Date Progress

While I have been consistently tracking my dividends in monthly articles, I feel it is useful also to provide the higher-level-view within each monthly rundown. Here are the monthly tabulations:

MonthDividends ($)

As we cap off two-thirds of 2019, I’ve managed to tip the dividend scales at just over $3,000. This leaves me in a great position to blow through 2018’s full-year sum of $3,752.39 (and $4,306.92 if including interest).

Market Activity

I have been sitting idly over the past month and just accumulating cash. I hate to see a month go by without any stock market purchases, but patience is an important trait as an investor. Making a purchase just to have something to write about would be imprudent. Still, I have been regularly following the daily market gyrations in hopes of an appetizing deal.


I received a new bonus interest offer from my online bank. They have upped the interest for me to 2.75% until the end of January 2020. While sitting in cash is never my overall goal as I would prefer to be putting most excess capital into stocks, the increased interest does help in the meantime.


I have decisions to make around whether to increase my ABBV position. The company is positioning itself for future revenues, but they have plenty to prove in the interim as far as getting through this acquisition effectively.

I remain well-situated from a cash balance perspective. Should the market offer up a lob of a pitch, I won’t hesitate to capitalize.

Thank you for reading.


Full Disclosure: Long REI.UN, CSH.UN, ABBV

Leave a Reply

Your email address will not be published. Required fields are marked *

CommentLuv badge


No recommendation to buy or sell is made on this website. Any and all transactions published here do not represent recommendations to buy or sell securities. Consult with an investment professional before you invest. Nothing on this website should be taken as advice. Any data or charts are presented for illustrative purposes only and no guarantee is made as to their accuracy or timeliness. We are not responsible or liable for any losses suffered as a result of your acting on what you have read here. Past performance is not a guarantee of future performance. Your investments can decline in value and may result in total loss of investment.

We will never add to a user’s comment, though we do reserve the right to delete or edit comments. This website is a positive environment for all users and will always remain that way.

Privacy Policy

We treat all details of a personal nature communicated to us by our readership as confidental unless otherwise indicated with express permission. Your contact information will never be revealed, shared, sold, or otherwise be leaked by us for any reason.

When posting a comment on this site, do not include personal details except those you wish to be displayed. Those who leave comments are entirely responsible for the content they post.

Visit Us On TwitterVisit Us On FacebookCheck Our Feed